Q-omics provides the consensus-scored DONSON profile across patient tissues and cancer cell-line models. DONSON expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DONSON is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, DONSON RNA expression shows 19,710 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where DONSON shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DONSON — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DONSON survival associations across molecular data types. DONSON RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DONSON RNA expression–survival associations across cancer types. High DONSON expression shows unfavorable associations in KIRC, ACC, MESO, KIRP, KICH and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DONSON RNA expression.
This table summarizes DONSON tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DONSON. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DONSON shows higher tumor expression in BLCA, HNSC, LUAD, KIRP, COAD and KIRC. The BLCA box plot shows higher DONSON RNA expression in tumor versus normal tissue (log2 FC = +2.118, t-test p < 0.001).
This table shows molecular features associated with DONSON in patient tissues and cancer cell lines. In patient samples, DONSON shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DONSON RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
